| Literature DB >> 32181173 |
Anukoon Kaewborisutsakul1, Thara Tunthanathip1, Pakorn Yuwakosol1, Srirat Inkate2, Sutthiporn Pattharachayakul3.
Abstract
CONTEXT: Venous thromboembolism (VTE), including deep-vein thrombosis (DVT) and pulmonary embolism (PE), is the fatal complication following spine surgery and the appropriate perioperative prophylaxis is still debated. AIMS: The aim of this study is to evaluate the incidence of along with risk factors for postoperative VTE in surgically treated extramedullary spinal tumor patients. SETTING AND DESIGNS: The study design involves single institute and retrospective cohort study. SUBJECTS AND METHODS: The cohort database was reviewed between the periods of January 2014 and June 2019. Patients undergoing surgery for spine tumor, extradural tumor, and intradural extramedullary were consecutively collected. STATISTICAL ANALYSIS USED: The incidence of VTE and clinical factors reported to be associated with VTE were identified, and then analyzed with an appropriate Cox regression model.Entities:
Keywords: Extramedullary tumor; plasma transfusion; spinal tumor; spine tumor; venous thromboembolism
Year: 2020 PMID: 32181173 PMCID: PMC7057870 DOI: 10.4103/ajns.AJNS_279_19
Source DB: PubMed Journal: Asian J Neurosurg
Baseline characteristics
| Characteristic | |
|---|---|
| Total number of patients | 103 |
| Gender | |
| Male | 40 (38.8) |
| Female | 63 (61.2) |
| Age | |
| Mean of age (years) | 49.9±17.0 |
| <50 | 47 (45.6) |
| ≥ 50 | 56 (54.4) |
| Comorbidities | |
| ASA classification | |
| 2 | 36 (35.0) |
| 3 | 67 (65.0) |
| BMI (kg/m2) | |
| <18.5 | 10 (9.7) |
| 18.5-<22.9 | 39 (37.9) |
| ≥23.0 | 54 (52.4) |
| Hypertension | 34 (33.0) |
| Dyslipidemia | 20 (19.4) |
| Diabetes mellitus | 14 (13.6) |
| Tobacco used | 11 (10.7) |
| Aspirin used | 5 (4.9) |
| Steroid used | 41 (39.8) |
| History of radiotherapy | 11 (10.7) |
| History of chemotherapy | 7 (6.8) |
| Operation data | |
| Type of surgery | |
| Laminectomy and tumor removal | 77 (74.8) |
| + Instrumentation | 26 (25.2) |
| Mean of operation time (mins) | 331.4±123.5 |
| Mean of EBL (ml) | 422.4±484.4 |
| Transfusion | |
| PRC transfusion | 26 (25.2) |
| FFP transfusion | 14 (13.6) |
| Platelet transfusion | 7 (6.8) |
| Ambulatory status | |
| | |
| Independent | 51 (49.5) |
| Dependent | 52 (50.5) |
| | |
| Independent | 58 (56.3) |
| Dependent | 41 (39.8) |
| Death | 4 (3.9) |
| VTE | |
| Screening DVT | 68 (66.0) |
| Prophylaxis VTE | |
| IPC alone | 40 (38.8) |
| LMWH alone | 4 (3.9) |
| IPC and LMWH | 16 (15.5) |
| VTE diagnosis | |
| DVT | 3 (2.9) |
| PE | 0 |
ASA – American Society of Anesthesiologists; BMI – Body mass index; EBL – Estimated blood loss; FFP – Fresh frozen plasma; PRC – Pack red cell; VTE – Venous thromboembolism; DVT – Deep-vein thrombosis; LMWH – Low molecular weight heparin; IPC – Intermittent pneumatic compression; PE – Pulmonary embolism
Type of pathology (n=103)
| Tumor pathology | |
|---|---|
| Spine tumor | |
| Metastasis | 21 (20.3) |
| Chordoma | 4 (3.8) |
| Lymphoma | 4 (3.8) |
| Cavernous hemangioma | 1 (1.0) |
| Sarcoma | 1 (1.0) |
| Intradural extramedullary tumor | |
| Schwannoma | 36 (35.0) |
| Meningioma | 27 (26.3) |
| Myxopapillary ependymoma | 2 (1.9) |
| Neurofibroma | 2 (1.9) |
| Germ cell tumor | 1 (1.0) |
| Ganglioneuroma | 1 (1.0) |
| Hemangiopericytoma | 1 (1.0) |
| MPNST | 1 (1.0) |
| Paraganglioma | 1 (1.0) |
MPNST – Malignant peripheral nerve sheath tumor
Deep-vein thrombosis patients’ characteristics (n=3)
| Case number | Patients factors and preoperative factors | Intraoperative factors | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, sex | Pathology | Spine level | Postoperator ambulatory | ASA class | BMI (kg/m2) | Smoking | Steroid use | Spinal instrument insertion | Operative time (mins) | EBL (ml) | FFP transfusion | |
| 1 | 21, female | Ganglioneuroma | C | Dependent | 2 | 23.2 | No | Yes | Yes | 230 | 150 | No |
| 2 | 57, female | Spinal metastasis | LS | Independent | 2 | 23.4 | No | No | Yes | 595 | 2000 | Yes |
| 3 | 66, male | Spinal metastasis | T | Dependent | 3 | 22 | Yes | Yes | Yes | 490 | 2000 | Yes |
| 1 | Independent | No | IPC | Asymptomatic | Proximal | 8 days | Anticoagulant | |||||
| 2 | Dependent | No | No | Leg edema | Proximal | 177 days | Anticoagulant | |||||
| 3 | Dependent | Yes (UTI) | IPC | Asymptomatic | Proximal | 75 days | Anticoagulant | |||||
C – Cervical; EBL – Estimated blood loss; IPC – Intermittent pneumatic compression; LS – Lumbrosacral; T – Thoracic; UTI – Urinary tract infection; DVT – Deep-vein thrombosis; FFP – Fresh frozen plasma; BMI – Body mass index
Figure 1The Kaplan–Meier curve for venous thromboembolism -free probabilities. (a) Kaplan–Meier curve for overall median venous thromboembolism-free time that has not yet been reached. (b) Kaplan–Meier curves shows venous thromboembolism-free probability was significantly lower in patients with operative times of 8 h, or more (blue line) (log-rank test, P = 0.005). (c) Kaplan–Meier curves shows venous thromboembolism-free probability was significantly lower in patients with fresh frozen plasma transfusion (blue line) (log-rank test, P = 0.002)
Cox regression analysis of venous thromboembolism occurrence
| Factor | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Gender | ||||
| Male | Ref | |||
| Female | 1.27 (0.12-14) | 0.85 | ||
| Age (years) | ||||
| <50 | Ref | |||
| ≥ 50 | 1.69 (0.15-18.65) | 0.67 | ||
| ASA classification | ||||
| 2 | Ref | |||
| 3 | 0.27 (0.03-3.01) | 0.29 | ||
| BMI | ||||
| < 23.0 | Ref | |||
| ≥ 23.0 | 1.90 (0.17-20.59) | 0.61 | ||
| Tobacco use | ||||
| No | Ref | |||
| Yes | 4.30 (0.39-47.52) | 0.23 | ||
| Aspirin use | ||||
| No | Ref | |||
| Yes | 0.46 (0-60.35) | 0.80 | ||
| Steroid | ||||
| No | Ref | |||
| Yes | 3.21 (0.29-35.40) | 0.34 | ||
| Postoperative radiotherapy | ||||
| No | Ref | |||
| Yes | 4.46 (0.40-49.22) | 0.22 | ||
| Type of surgery | ||||
| No instrumentation | Ref | |||
| Instrumentation | 579.88 (0-1963472609.91) | 0.41 | ||
| Operative time (h) | ||||
| <8 h | Ref | |||
| ≥ 8 h | 13.98 (1.27-154.40) | 0.03 | 9.95 (0.86-115.30) | 0.066 |
| EBL (mL) | ||||
| <400 | Ref | |||
| ≥400 | 3.35 (0.30-36.95) | 0.32 | ||
| FFP transfusion | ||||
| No | Ref | |||
| Yes | 16.38 (1.47-182.23) | 0.023 | 11.77 (1.01-138.1) | 0.049 |
| Ambulation status | ||||
| Preoperative | ||||
| Independent | Ref | |||
| Dependent | 2.16 (0.20-23.83) | 0.53 | ||
| Postoperative* | ||||
| Independent | Ref | |||
| Dependent | 0.74 (0.07-8.16) | 0.81 | ||
| DVT prophylaxis | ||||
| No | Ref | |||
| Yes | 1.50 (0.14-16.45) | 0.74 | ||
| Schwannoma | ||||
| No | Ref | |||
| Yes | 0.03 (0-497.14) | 0.47 | ||
*Death cases were excluded. HR – Hazard ratio; CI – Confidence interval; DVT – Deep-vein thrombosis; EBL – Estimated blood loss; BMI – Body mass index; Ref - Reference
Figure 2Violin plots demonstrate the non-parametric data of estimated blood loss in fresh frozen plasma transfusion and non-transfusion group. The median of estimated blood loss in fresh frozen plasma transfusion group was higher (950 mL vs. 300 mL). Wilcoxon Rank sums test found significantly different (P < 0.001)